An interventional study of REMINDER4Care in Dementia Risk Factors, Prevention and Cognitive Health, sponsored by University of Coimbra. Recruiting at 1 site in Portugal. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by University of Coimbra · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Dementia with a site in Portugal — 9 open to participants now, 9 under way, 1 of them phase 3. Dementia · Portugal.
Among the 34 studies in Dementia with a site in Portugal, this one is the 16th largest by planned enrollment of the 30 interventional ones that give a count, is one of 6 that started in 2025, is one of 24 with no phase, and was the 28th registered.
2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.
Browse Dementia studies →9 of the 34 studies in Dementia with a site in Portugal are open now. Recruiting first, the newest first:
University Rovira i Virgili · Sites in Portugal
Ages 18+
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Portugal, Australia, Austria and 14 more countries
Ages 18+
Universidade do Porto · Sites in Portugal
Ages 65+ · Healthy volunteers
Eduarda Oliosi, MS · Sites in Portugal
Ages 55+
MapLight Therapeutics · Sites in Portugal, United States, Argentina and 12 more countries
Ages 55–90
A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →
Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 90 across 1,761 interventional studies indexed under Dementia.
Median enrollment 104 across the 30 interventional studies, 176 across the 4 observational. Of the 19 that completed or were terminated, 3 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 34 have an industry lead sponsor. The 10 most frequent:
University of Coimbra is the lead sponsor of 89 studies on the registry; 27 are open to participants now.
University of Coimbra has 1 study filed under Dementia — fewer than ten, so there is no comparison to draw.
1 of the studies in Dementia with a site in Portugal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07577440University Rovira i VirgiliEffectiveness of the Self-Control Module of a Positive Mental Health Promotion Programme for Adult Informal Caregivers of People With Dementia: Protocol for a Randomised Controlled Trial | 2027-05-02 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies in Dementia with a site in Portugal, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Dementia incidence is rising, posing a public health challenge, but 45% of cases can be prevented by addressing modifiable risk factors. Multidomain trials show that lifestyle changes can improve cognitive function and reduce dementia risk (like the FINGER trial). The REMINDER program, a Portuguese-based dementia risk reduction protocol, was developed for community-dwelling older adults aged 55 and above. However, older adults in Residential and Daycare Facilities (RDF) have distinct needs that demand program adaptation to ensure its relevance and effectiveness. In addition, more studies are needed to evaluate the impact of multidomain interventions with older adults in RDF.
To address these challenges, the REMINDER4Care program was developed as a tailored, multidomain intervention to reduce dementia risk. It emphasizes social and cognitive engagement and advances its adaptation and evaluation in Residential and Daycare Facilities (RDF). To assess efficacy, the investigators will perform a Randomized Controlled Trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this arm, participants will receive the intervention - REMINDER4Care. REMINDER4Care is a 20-session group program that includes psychoeducation about the brain, social skills training, using cognitive aids, setting personal goals, and practicing mindfulness.
Other: REMINDER4Care
In this arm, participants will be a waiting-list group and receive the REMINDER4Care interventions after the study ends (after the post-interventions).
REMINDER4Care was an adapted version of the original REMINDER program, tailored to the characteristics, needs, and interests of older adults in RDF. The REMINDER4Care intervention includes 20 face-to-face group sessions, each approximately 60 to 75 minutes, held twice a week over ten weeks. This program aims to optimize memory, attention, executive function, and emotional regulation while promoting lifestyle habits that protect the aging brain. The sessions include brain health education, cognitive exercises, compensatory memory strategies, training for managing personally relevant goals (with goal setting), and stress management techniques (compassion-based therapies, relaxation methods, and mindfulness). Social support and emotion regulation strategies (like attention management, positive cognitive reappraisal, and reframing speech) were included to address psychosocial risk factors like stress, social isolation, and depression.
Screening
Participants' sociodemographic (e.g., age, marital status, education level) and clinical (presence of medical diagnosis, current medication, sensory issues, mobility deficits, substance use, and hospitalization).
Time frame: Screening
Screening
Dementia risk was assessed using the Lifestyle for BRAin health (LIBRA) score, which ranges from -2.1 to 10.6, with higher scores indicating a greater risk of developing dementia.
Time frame: Screening
Cognitive status
Global cognition was assessed using Addenbrooke's Cognitive Examination - Revised (ACE-R), a scale with scores ranging from 0 to 100, where higher scores indicate better cognitive functioning.
Time frame: Screening and 1-week and 3-months post-intervention
Mood status
Depressive Symptoms: Assessed using the Geriatric Depression Scale (GDS-30), a 30-item scale with scores ranging from 0 to 30, where higher scores indicate greater depressive symptoms.
Time frame: Screening and 1-week and 3-months post-intervention
Cognitive status
Processing Speed: Evaluated with the Symbol Search subtest of the WAIS-III, scored by correct responses within a time limit, with higher scores representing faster processing speed.
Time frame: Baseline and 1-week and 3-months post-intervention
Cognitive status
Verbal Initiative: Measured with the Verbal Fluency Test (letters M, R, and alternate category), scored by the number of correct words produced, with higher scores indicating greater verbal initiative.
Time frame: Baseline and 1-week and 3-months post-intervention
Perceived social isolation and loneliness
Loneliness: Measured with the UCLA Loneliness Scale (UCLA LS-3), the score was 20 to 80, with higher scores reflecting greater perceived loneliness.
Time frame: Baseline and 1-week and 3-months post-intervention
Perceived social network
Social Networks: Evaluated using Lubben's Brief Social Network Scale (LSNS-6), scored from 0 to 30, where higher scores indicate a stronger social network.
Time frame: Baseline and 1-week and 3-months post-intervention
Functionality status
Functional abilities: This is measured using the IAFAI (Informant Assessment of Functioning in Aging and Intellectual Disabilities).
Time frame: Baseline and 1-week and 3-months post-intervention
Perceived quality of life
Psychological Well-Being: Assessed using the EBEP-R is a short version of the Psychological Well-Being Scale. Higher scores on the EBEP-R indicate better psychological well-being.
Time frame: Baseline and 1-week and 3-months post-intervention
Plan to share: Undecided — Open science plans will involve sharing IPD with other researchers, clearly anonymized, to promote the study's replication. The investigators are still developing the strategy for data sharing and will update as soon as it is defined.
No publications or documents are linked to this record.
Ran from May 2025 to primary completion in Jul 2025, 2 months.
Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 2 months is below that.
Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Coimbra